Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.

Archer, R., Tappenden, P., Ren, S. et al. (8 more authors) (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technoogyl Assessment, 20. 39. ISSN 1366-5278

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Dates:
  • Published: May 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 31 May 2016 12:55
Last Modified: 31 May 2016 12:55
Published Version: http://dx.doi.org/10.3310/hta20390
Status: Published
Publisher: NIHR Health Technology Assessment Programme
Refereed: Yes
Identification Number: https://doi.org/10.3310/hta20390
Related URLs:

Share / Export

Statistics